Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RG 7882

Drug Profile

RG 7882

Alternative Names: D-4064A; DMUC 4064A; RG7882

Latest Information Update: 02 Aug 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genentech
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Membrane protein inhibitors; Tumour-associated carbohydrate antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Ovarian cancer; Pancreatic cancer

Most Recent Events

  • 26 Jul 2018 Discontinued - Phase-I for Ovarian cancer (Second-line therapy or greater) in USA (IV) (Roche pipeline, July 2018)
  • 26 Jul 2018 Discontinued - Phase-I for Pancreatic cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Recurrent) in USA (IV) (Roche pipeline, July 2018)
  • 18 Jun 2018 Genentech completes a phase I trial in Pancreatic cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Recurrent) and Ovarian Cancer (Second line therapy or greater) in USA (IV) (NCT02146313)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top